Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $267 price target.
Share
Why It Matters
A big investment bank thinks Revolution Medicines is worth buying again. When experts start liking a stock again, it can mean they found good reasons to feel hopeful.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.